Multiple Sclerosis Drugs - Finland

Finland

The Multiple Sclerosis Drugs market in Finland is expected to see a projected revenue of US$39.51m in 2024.
Furthermore, it is anticipated that the market will experience an annual growth rate (CAGR 2024-2029) of 0.76%, leading to a market volume of US$41.04m by 2029.
When compared on a global scale, United States is expected to generate the highest revenue of US$11,770.00m in 2024.
Finland is witnessing a surge in the demand for innovative multiple sclerosis drugs, driven by the country's strong focus on healthcare and research.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Finland has been seeing a steady growth in recent years. Finland has one of the highest rates of Multiple Sclerosis (MS) in the world, with over 7000 people living with MS in the country. This has resulted in a high demand for MS drugs, leading to the growth of the market.

Customer preferences: Patients in Finland prefer MS drugs that are effective in managing the symptoms of the disease while having minimal side effects. They also prefer drugs that are convenient to use and do not require frequent administration. With the availability of a wide range of drugs in the market, patients have the option to choose drugs that suit their preferences.

Trends in the market: The market for MS drugs in Finland has been witnessing a shift towards the use of newer and more advanced drugs. These drugs have been developed using advanced technologies and have shown promising results in clinical trials. They offer better efficacy in managing the symptoms of MS and have fewer side effects compared to older drugs. The trend towards the use of newer drugs is expected to continue in the coming years.

Local special circumstances: Finland has a well-established healthcare system that provides access to MS drugs for patients. The government provides subsidies for MS drugs, making them affordable for patients. This has led to a high demand for MS drugs in the country. In addition, Finland has a high prevalence of MS, which has resulted in a large patient pool for MS drugs.

Underlying macroeconomic factors: The growth of the MS drugs market in Finland is driven by several macroeconomic factors. The country has a high GDP per capita, which translates to a higher purchasing power for consumers. This has resulted in a higher demand for MS drugs in the country. In addition, Finland has a well-developed healthcare system that provides access to MS drugs for patients. The government also provides subsidies for MS drugs, making them affordable for patients. These factors have contributed to the growth of the MS drugs market in Finland.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.